Effect of dipeptidyl peptidase-4 inhibitor to the additional secretion of insulin in type 2 diabetic patients on hemodialysis

Effect of dipeptidyl peptidase-4 inhibitor to the additional secretion of insulin in type 2 diabetic patients on hemodialysis - Effect of dipeptidyl peptidase-4 inhibitor to the additional secretion of insulin in type 2 diabetic patients on hemodialysis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006024

Enrollment

Registered

2011-07-25

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetic patients on hemodialysis

Interventions

Observation span : 12 weeks Intervention : Vildagliptin (Equa) Dose : 50mg once daily for a week after starting and 50mg twice daily after 2weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients on hemodialysis with only dietary therapy who showed HbA1c(JDS) <8.0% and postprandial glucose concentration >180mg/dl

Exclusion criteria

Exclusion criteria: (1)Type 2 diabetic patients who received insulin therapy or oral hypoglycemic agents or Liraglutide. (2) Type 2 diabetic patients who have been treated with DPP-4 inhibitor. (3) Type 1 diabetic patients. (4) Patients who develop serious hyperglycemia or diabetic ketoacidosis. (5) Patients with nephrotic syndrome. (6) Patients with treatments of steroids or immunosuppressive agents or antifungal or HIV protease inhibitors. (7) Patients with severe complications in cardiovascular system within 6 months before study entry. (8) Patients with liver diseases. (9) Patients with cancer diseases. (10) Patients with pregnancy , possibility of pregnancy . (11) Patients who are deemed to be inappropriate by the investigators.

Design outcomes

Primary

Measure	Time frame
Changes in levels of HbA1c(JDS), glycoalbumin, plasma glucose along with the comparison of the results obtained from glucagon load test and 75g oral glucose tolerance test after 12weeks treatment from the baseline.	—

Secondary

Measure	Time frame
Changes in serum levels of inflammatory markers, body weight, body fat percentage, skeletal muscle mass measured with In Body S20.	—

Countries

Japan

Contacts

Public ContactSachie Hirose

Chibune general hospital Nephrology

06-6471-9541

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026